Travere Therapeutics Inc to Discuss the Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Travere Therapeutics Inc. top line results from the ongoing Phase I/II COMPOSE Study. (Operator Instructions)
I would now like to turn the call over to your host, Chris Cline. You may begin.
Thank you, Kevin. Good morning, and thank you all for joining us on short notice today to talk about the positive top line results from the ongoing COMPOSE Study of pegtibatinase in classical homocystinuria. A copy of the press release announcing the results is available on our website. Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined by Dr. Bill Rote, Senior Vice President of Research and Development.
Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |